Show simple item record

dc.contributor.advisorVan Ghelue, Marijke
dc.contributor.authorJarhelle, Elisabeth
dc.date.accessioned2018-05-31T11:12:55Z
dc.date.available2018-05-31T11:12:55Z
dc.date.issued2018-06-01
dc.description.abstractIt is estimated that 5-10% of breast cancers (BC) and 25% of ovarian cancers (OC) are caused by inherited sequence variants in genes. In the mid 90’s, the two genes BRCA1 and BRCA2 were discovered to be directly associated with increased risk of BC and OC. Molecular screening of these two genes has revealed several disease causing variants as well as variants of unknown clinical significance (VUS). In this study, we investigated several BRCA1/2 VUSs for their impact on gene expression and protein product. Additionally, we investigated patients with BC and/or OC for disease causing variants in 92 additional genes. We identified five BRCA1/2 variants affecting the gene expression and/or protein product and further identified 13 patients with disease causing variants in other genes, demonstrating the need for broader genetic evaluation of patients with BC and OC.en_US
dc.description.doctoraltypeph.d.en_US
dc.description.popularabstractIt is estimated that 5-10% of breast cancers (BC) and 25% of ovarian cancers (OC) are caused by inherited sequence variants in genes. In the mid 90’s, the two genes BRCA1 and BRCA2 were discovered to be directly associated with increased risk of BC and OC. Molecular screening of these two genes has revealed several disease causing variants as well as variants of unknown clinical significance (VUS). In this study, we investigated several BRCA1/2 VUSs for their impact on gene expression and protein product. Additionally, we investigated patients with BC and/or OC for disease causing variants in 92 additional genes. We identified five BRCA1/2 variants affecting the gene expression and/or protein product and further identified 13 patients with disease causing variants in other genes, demonstrating the need for broader genetic evaluation of patients with BC and OC.en_US
dc.description.sponsorshipHelse Nord; Barne- og ungdomsklinikken, Universitetssykehuset Nord-Norge; Odd Fellowen_US
dc.descriptionThe papers II and III are not available in Munin. <br> Paper I: Jarhelle, E., Stensland, H. M. F. R., Mæhle, L. & Van Ghelue, M. (2017). Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort. Available in <a href=http://dx.doi.org/10.1007/s10689-016-9916-2> Familial Cancer, 16(1): p. 1-16. </a> Manuscript version available in Munin at <a href=http://hdl.handle.net/10037/10579> http://hdl.handle.net/10037/10579 </a>. <br> Paper II: Jarhelle, E., Stensland, H. M. F. R. & Van Ghelue, M. Comparing the quality of RNA preserved in PAXgene and Tempus Blood RNA tubes using BRCA1 splicing events as a model system. (Manuscript). <br> Paper III: Jarhelle, E., Stensland, H. M.F. R., Hansen, G. Å. M., Skarsfjord, S., Jonsrud, C., Ingebrigtsen, M., Strømsvik, N. & Van Ghelue, M. Identifying sequence variants contributing to hereditary breast/ovarian cancer in BRCA1/2 negative breast and ovarian cancer patients. (Manuscript).en_US
dc.identifier.urihttps://hdl.handle.net/10037/12811
dc.language.isoengen_US
dc.publisherUiT The Arctic University of Norwayen_US
dc.publisherUiT Norges arktiske universiteten_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2018 The Author(s)
dc.subject.courseIDDOKTOR-003
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Medisinsk genetikk: 714en_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Medical genetics: 714en_US
dc.titleWhat are the molecular consequences of germline mutations in breast and ovarian cancer susceptibility genes in a Norwegian breast and ovarian cancer population?en_US
dc.typeDoctoral thesisen_US
dc.typeDoktorgradsavhandlingen_US


File(s) in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record